サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：メッセンジャーRNA（mRNA）ワクチン・治療薬の世界市場：規模、予測（2023年～2028年）、業界動向、成長、インフレの影響、企業機会分析
市場調査レポート
商品コード
1163925

メッセンジャーRNA（mRNA）ワクチン・治療薬の世界市場：規模、予測（2023年～2028年）、業界動向、成長、インフレの影響、企業機会分析

Messenger RNA (mRNA) Vaccines & Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
出版日: | 発行: Renub Research | ページ情報: 英文 125 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
メッセンジャーRNA（mRNA）ワクチン・治療薬の世界市場：規模、予測（2023年～2028年）、業界動向、成長、インフレの影響、企業機会分析
出版日: 2022年11月01日
発行: Renub Research
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のメッセンジャーRNA（mRNA）ワクチン・治療薬の市場規模は、2028年までに263億4,000万米ドルに達し、2022年～2028年にかけて14.60％のCAGRで拡大すると予測されています。

世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場の開発を推進する重要な要因の1つは、医療疾患の有病率の増加です。それに加え、ウイルス性疾患に対する治療薬やワクチンの需要が高まっていることも、業界に利益をもたらしています。また、COVID-19のmRNAワクチン・治療薬の発売と普及により、2020年はmRNA技術プラットフォームにとって分岐点となり、その結果、2020年までにmRNAプラットフォームの合計市場評価額は急速に上昇しました。

当レポートでは、世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場について調査分析し、市場力学、セグメント別・地域別の分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長促進要因
  • 課題
  • 機会

第5章 世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場

第6章 シェア分析：世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場

  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第7章 世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場：タイプ別

  • 感染予防mRNAワクチン
  • 感染症治療mRNAワクチン
  • 個別化がん治療mRNAワクチン
  • がん治療mRNAワクチンの標準化

第8章 世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場：用途別

  • がん
  • 感染症
  • その他

第9章 世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場：エンドユーザー別

  • 病院
  • クリニック
  • 診断センター
  • その他

第10章 世界のメッセンジャーRNA（mRNA）ワクチン・治療薬市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 世界のその他の地域

第11章 主要企業

  • Pfizer
  • GlaxoSmithKline's
  • Daiichi Sankyo Company, Limited.
  • Intellia Therapeutics
  • Moderna Inc
  • CureVac N.V.
  • Arcturus Therapeutics Holdings
  • BioNTech
図表

List of Figures

  • Figure-01: Global - Messenger RNA (mRNA) Vaccines & Therapeutics Market (Billion US$), 2017 - 2022
  • Figure-02: Global - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market (Billion US$), 2023 - 2028
  • Figure-03: Type - Infection Prevention mRNA Vaccine Market (Million US$), 2017 - 2022
  • Figure-04: Type - Forecast for Infection Prevention mRNA Vaccine Market (Million US$), 2023 - 2028
  • Figure-05: Type - Infectious Disease Treatment mRNA Vaccine Market (Million US$), 2017 - 2022
  • Figure-06: Type - Forecast for Infectious Disease Treatment mRNA Vaccine Market (Million US$), 2023 - 2028
  • Figure-07: Type - Individualized Cancer Treatment mRNA Vaccine Market (Million US$), 2017 - 2022
  • Figure-08: Type - Forecast for Individualized Cancer Treatment mRNA Vaccine Market (Million US$), 2023 - 2028
  • Figure-09: Type - Standardization of Cancer Treatment mRNA Vaccine Market (Million US$), 2017 - 2022
  • Figure-10: Type - Forecast for Standardization of Cancer Treatment mRNA Vaccine Market (Million US$), 2023 - 2028
  • Figure-11: Application - Cancer Market (Million US$), 2017 - 2022
  • Figure-12: Application - Forecast for Cancer Market (Million US$), 2023 - 2028
  • Figure-13: Application - Infectious Diseases Market (Million US$), 2017 - 2022
  • Figure-14: Application - Forecast for Infectious Diseases Market (Million US$), 2023 - 2028
  • Figure-15: Application - Others Market (Million US$), 2017 - 2022
  • Figure-16: Application - Forecast for Others Market (Million US$), 2023 - 2028
  • Figure-17: End User - Hospital Market (Million US$), 2017 - 2022
  • Figure-18: End User - Forecast for Hospital Market (Million US$), 2023 - 2028
  • Figure-19: End User - Clinics Market (Million US$), 2017 - 2022
  • Figure-20: End User - Forecast for Clinics Market (Million US$), 2023 - 2028
  • Figure-21: End User - Diagnostics Centers Market (Million US$), 2017 - 2022
  • Figure-22: End User - Forecast for Diagnostics Centers Market (Million US$), 2023 - 2028
  • Figure-23: End User - Others Market (Million US$), 2017 - 2022
  • Figure-24: End User - Forecast for Others Market (Million US$), 2023 - 2028
  • Figure-25: North America - Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2017 - 2022
  • Figure-26: North America - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2023 - 2028
  • Figure-27: Europe - Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2017 - 2022
  • Figure-28: Europe - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2023 - 2028
  • Figure-29: Asia-Pacific - Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2017 - 2022
  • Figure-30: Asia-Pacific - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2023 - 2028
  • Figure-31: Rest of the World - Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2017 - 2022
  • Figure-32: Rest of the World - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market (Million US$), 2023 - 2028
  • Figure-33: Pfizer - Global Revenue (Billion US$), 2017 - 2022
  • Figure-34: Pfizer - Forecast for Global Revenue (Billion US$), 2023 - 2028
  • Figure-35: GlaxoSmithKline's - Global Revenue (Billion US$), 2017 - 2022
  • Figure-36: GlaxoSmithKline's - Forecast for Global Revenue (Billion US$), 2023 - 2028
  • Figure-37: Daiichi Sankyo Company, Limited. - Global Revenue (Billion US$), 2017 - 2022
  • Figure-38: Daiichi Sankyo Company, Limited. - Forecast for Global Revenue (Billion US$), 2023 - 2028
  • Figure-39: Intellia Therapeutics - Global Revenue (Million US$), 2017 - 2022
  • Figure-40: Intellia Therapeutics - Forecast for Global Revenue (Million US$), 2023 - 2028
  • Figure-41: Moderna Inc - Global Revenue (Million US$), 2017 - 2022
  • Figure-42: Moderna Inc - Forecast for Global Revenue (Million US$), 2023 - 2028
  • Figure-43: CureVac N.V. - Global Revenue (Million US$), 2017 - 2022
  • Figure-44: CureVac N.V. - Forecast for Global Revenue (Million US$), 2023 - 2028
  • Figure-45: Arcturus Therapeutics Holdings - Global Revenue (Million US$), 2017 - 2022
  • Figure-46: Arcturus Therapeutics Holdings - Forecast for Global Revenue (Million US$), 2023 - 2028
  • Figure-47: BioNTech - Global Revenue (Million US$), 2017 - 2022
  • Figure-48: BioNTech - Forecast for Global Revenue (Million US$), 2023 - 2028

List of Tables

  • Table-01: Global - Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by Type (Percent), 2017 - 2022
  • Table-02: Global - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by Type (Percent), 2023 - 2028
  • Table-03: Global - Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by Application (Percent), 2017 - 2022
  • Table-04: Global - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by Application (Percent), 2023 - 2028
  • Table-05: Global - Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by End User (Percent), 2017 - 2022
  • Table-06: Global - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by End User (Percent), 2023 - 2028
  • Table-07: Global - Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by Region (Percent), 2017 - 2022
  • Table-08: Global - Forecast for Messenger RNA (mRNA) Vaccines & Therapeutics Market Share by Region (Percent), 2023 - 2028
目次

Global Messenger RNA (mRNA) Vaccines & Therapeutics Market will reach US$ 26.34 Billion by 2028. Messenger Ribonucleic Acid (mRNA) is a term that refers to a single protein-coding gene in the genome that conforms as the basis for protein synthesis in cells. mRNA vaccines and treatments are made in laboratories utilizing mammalian cells and have favorable immunological characteristics. Infection prevention mRNA vaccines, infectious disease treatment mRNA vaccines, customized cancer therapy mRNA vaccines, and standardization of cancer treatment mRNA vaccines are frequent types of vaccinations and therapies. They are injected into the body to activate virus-detecting immunological sensors and cause the cells to generate viral antigen proteins. This improves B- and T-cell responses, which helps the body's immunity.

Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Size will expand at a CAGR of 14.60% from 2022 to 2028:

mRNA vaccines and treatments are generated employing new technologies that are more effective against infections, have higher potency, improved immunogenicity, and are relatively more cost-effective than conventional pharmaceuticals. One of the critical factors propelling the development of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market is the increased prevalence of medical disorders such as diabetes, TB, cancer, and cardiovascular diseases (CVDs). In addition, the industry also benefits from rising demand for therapeutic drugs and vaccines for Ebola, influenza, HIV, and other viral illnesses.

Evolution of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Industry amidst Pandemic:

With the launch and widespread usage of mRNA vaccines and therapies for COVID-19, 2020 marked a watershed moment for mRNA technology platforms. As a result, the combined market valuation of mRNA platforms had increased fast by 2020. The increase in market value reflects expectations that mRNA technology will give far more than the current COVID-19 preventive vaccines. According to Renub Research, the Global Messenger RNA (mRNA) Vaccines and Therapeutics Market was valued at US$ 11.63 Billion in 2022.

Global Messenger RNA (mRNA) Vaccines & Therapeutics Market: Segmentation Analysis:

By Type, the market is bifurcated into Infection Prevention mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine, and Standardization of Cancer Treatment mRNA Vaccine.

By Application, Cancer, Infectious Diseases, and Others are the major segments covered in our report. As per our estimates, Infectious Diseases hold a significant share in the market and are estimated to remain dominant throughout the forecasted period.

By End User, we have studied the market for hospitals, Clinics, Diagnostics Centers, and Others. As per our analysis, clinics and diagnostic centers are gaining traction with the advancement of technology applications. However, hospitals tend to remain dominant throughout the study period.

By Region, North America, Europe, Asia-Pacific, and Rest of the World. During the forecast period, North America is estimated to monopolize the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market. The market in North America is contrived by an increase in demand for COVID-19 mRNA vaccines, major players operating in the US, and an exponential rise in the number of COVID-19 cases in the US.

Key Players:

Pfizer, GlaxoSmithKline, Daiichi Sankyo Company, Limited, Intellia Therapeutics, Moderna Inc, CureVac N.V., Arcturus Therapeutics Holdings, and BioNTech are the prominent companies in the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market examined in our analysis. In addition, we have discussed the competition landscape section of the study, which included an overview, the latest development strategies, and market revenue analysis of the above-mentioned worldwide companies. Surprisingly, the major firms invest in mRNA technologies since they can integrate numerous molecules into a therapeutic drug, which is a huge growth factor.

Renub Research latest report "Global Messenger RNA (mRNA) Vaccines & Therapeutics Market, Global Forecast By Type (Infection Prevention mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine and Standardization of Cancer Treatment mRNA Vaccine), Application (Cancer, Infectious Diseases and Others), End User (Hospital, Clinics, Diagnostics Centers and Others), Region (North America, Europe, Asia-Pacific and Rest of the World), Companies (Pfizer, GlaxoSmithKline, Daiichi Sankyo Company, Limited, Intellia Therapeutics, Moderna Inc, CureVac N.V., Arcturus Therapeutics Holdings, and BioNTech)" provides a detailed analysis of Global Messenger RNA (mRNA) Vaccines & Therapeutics Industry.

Type - The market has been studied from 4 viewpoints:

  • 1. Infection Prevention mRNA Vaccine
  • 2. Infectious Disease Treatment mRNA Vaccine
  • 3. Individualized Cancer Treatment mRNA Vaccine
  • 4. Standardization of Cancer Treatment mRNA Vaccine

Application - The market has been studied from 3 viewpoints:

  • 1. Cancer
  • 2. Infectious Diseases
  • 3. Others

End Use - The market has been studied from 4 viewpoints:

  • 1. Hospital
  • 2. Clinics
  • 3. Diagnostics Centers
  • 4. Others

Region - The market has been studied from 4 viewpoints:

  • 1. North America
  • 2. Europe
  • 3. Asia-Pacific
  • 4. Rest of the World

Company Insights:

  • Overview
  • Recent Development
  • Revenue

Key Players:

  • 1. Pfizer
  • 2. GlaxoSmithKline's
  • 3. Daiichi Sankyo Company, Limited.
  • 4. Intellia Therapeutics
  • 5. Moderna Inc
  • 6. CureVac N.V.
  • 7. Arcturus Therapeutics Holdings
  • 8. BioNTech

Table of Contents

1. Introduction

2. Research& Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges
  • 4.3 Opportunities

5. Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

6. Share Analysis - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

  • 6.1 By Type
  • 6.2 By Application
  • 6.3 By End User
  • 6.4 By Region

7. Type - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

  • 7.1 Infection Prevention mRNA Vaccine
  • 7.2 Infectious Disease Treatment mRNA Vaccine
  • 7.3 Individualized Cancer Treatment mRNA Vaccine
  • 7.4 Standardization of Cancer Treatment mRNA Vaccine

8. Application - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

  • 8.1 Cancer
  • 8.2 Infectious Diseases
  • 8.3 Others

9. End User - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

  • 9.1 Hospital
  • 9.2 Clinics
  • 9.3 Diagnostics Centers
  • 9.4 Others

10. Region - Global Messenger RNA (mRNA) Vaccines & Therapeutics Market

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 Rest of the World

11. Key Players

  • 11.1 Pfizer
    • 11.1.1 Overview
    • 11.1.2 Recent Development
    • 11.1.3 Revenue
  • 11.2 GlaxoSmithKline's
    • 11.2.1 Overview
    • 11.2.2 Recent Development
    • 11.2.3 Revenue
  • 11.3 Daiichi Sankyo Company, Limited.
    • 11.3.1 Overview
    • 11.3.2 Recent Development
    • 11.3.3 Revenue
  • 11.4 Intellia Therapeutics
    • 11.4.1 Overview
    • 11.4.2 Recent Development
    • 11.4.3 Revenue
  • 11.5 Moderna Inc
    • 11.5.1 Overview
    • 11.5.2 Recent Development
    • 11.5.3 Revenue
  • 11.6 CureVac N.V.
    • 11.6.1 Overview
    • 11.6.2 Recent Development
    • 11.6.3 Revenue
  • 11.7 Arcturus Therapeutics Holdings
    • 11.7.1 Overview
    • 11.7.2 Recent Development
    • 11.7.3 Revenue
  • 11.8 BioNTech
    • 11.8.1 Overview
    • 11.8.2 Recent Development
    • 11.8.3 Revenue